•INNOVATIVE CELL THERAPIES — The first scalable, effective solutions for liver failure.

•BREAKTHROUGH PRODUCT — HX-001 regenerates functional liver tissue — clinically and commercially viable.

•EFFICIENT MANUFACTURING — Scalable, consistent, and cost-controlled; 70% cheaper than transplant.

•PRESTIGIOUS BACKING — Stanford StartX, Y Combinator Alumni, and Mayo Clinic partnerships drive rapid execution.

•HIGH MARKET POTENTIAL — Addressing a $20B+ global unmet need.